Clinical Treatment of Transcranial Direct Current Stimulation in Older Adolescents With Amblyopia

Launched by TIANJIN EYE HOSPITAL · Jan 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for amblyopia, often called "lazy eye," in older adolescents and young adults. Amblyopia can lead to serious vision problems, especially if it's not treated early. Researchers want to see if a method called transcranial direct current stimulation (tDCS) can improve vision in people aged 10 to 30 with this condition. This treatment uses a gentle electrical current to help the brain's visual areas work better. The trial will measure how this treatment affects vision and brain activity using special tests and scans.

To be eligible for the trial, participants need to be between 10 and 30 years old and have a specific type of amblyopia, where there is a significant difference in vision between the two eyes. They should not have any other eye diseases or conditions that could affect their vision. During the trial, participants will receive the tDCS treatment and undergo various assessments to track their progress. This study aims to find a safe and effective way to help improve vision in young people with amblyopia, potentially offering new hope for those who have not responded well to traditional treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children and their legal guardians have obtained consent in writing.
• • Participants aged 10-30, of any gender.
• • Participants must meet the diagnostic criteria for amblyopia: unilateral amblyopia with a difference of two lines or more in visual acuity between the eyes, or bilateral amblyopia with best-corrected visual acuity worse than 20/30 (or worse than 0.2 logMAR). The visual acuity charts to be used are LEA SYMBOLS® (Good-Lite Co., Elgin, IL) or HOTV visual acuity chart.
• Exclusion Criteria:
• • Participants who may have eye diseases affecting vision or refractive errors (such as cataracts, crystalline lens damage, glaucoma, macular degeneration, corneal disorders, retinitis pigmentosa, retinal detachment, severe vitreous opacities, etc
• • History of eye trauma or intraocular surgery
• • Inability to cooperate with examinations
• • Presence of concomitant systemic diseases (such as epilepsy)
• • Participation in any other experimental treatment within the past 3 months
• • Other situations deemed unsuitable by the investigator.